These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 14631611)

  • 1. Toward rapproachment in the placebo control debate. A calculated compromise of power.
    Leon AC; Solomon DA
    Eval Health Prof; 2003 Dec; 26(4):404-14. PubMed ID: 14631611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What makes placebo-controlled trials unethical?
    Miller FG; Brody H
    Am J Bioeth; 2002; 2(2):3-9. PubMed ID: 12189059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics.
    D'Agostino RB; Massaro JM; Sullivan LM
    Stat Med; 2003 Jan; 22(2):169-86. PubMed ID: 12520555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal sample allocation in clinical trials designed to investigate relative risks.
    Eastwood BJ
    Stat Med; 1996 Dec; 15(23):2523-38. PubMed ID: 8961461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blinding protocols, treatment credibility, and expectancy: methodologic issues in clinical trials of osteopathic manipulative treatment.
    Licciardone JC; Russo DP
    J Am Osteopath Assoc; 2006 Aug; 106(8):457-63. PubMed ID: 16943515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Questioning the methodologic superiority of 'placebo' over 'active' controlled trials.
    Howick J
    Am J Bioeth; 2009 Sep; 9(9):34-48. PubMed ID: 19998192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and factors associated with use of placebo control groups in randomized controlled trials in psoriasis: a cross-sectional study.
    Katz KA; Karlawish JH; Chiang DS; Bognet RA; Propert KJ; Margolis DJ
    J Am Acad Dermatol; 2006 Nov; 55(5):814-22. PubMed ID: 17052487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
    Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
    Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redefining the randomized controlled trial in the context of acupuncture research.
    Walji R; Boon H
    Complement Ther Clin Pract; 2006 May; 12(2):91-6. PubMed ID: 16648085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Congratulations, you have been randomized into the control group!(?)": issues to consider when recruiting schools for matched-pair randomized control trials of prevention programs.
    Ji P; DuBois DL; Flay BR; Brechling V
    J Sch Health; 2008 Mar; 78(3):131-9. PubMed ID: 18307608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Historical control monotherapy design in the treatment of epilepsy.
    French JA; Wang S; Warnock B; Temkin N
    Epilepsia; 2010 Oct; 51(10):1936-43. PubMed ID: 20561024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can placebo controls reduce the number of nonresponders in clinical trials? A power-analytic perspective.
    Leon AC
    Clin Ther; 2001 Apr; 23(4):596-603. PubMed ID: 11354393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot seminar on ethical issues in clinical trials for cancer researchers in Vietnam.
    Love RR; Fost N
    IRB; 2003; 25(6):8-10. PubMed ID: 15035249
    [No Abstract]   [Full Text] [Related]  

  • 15. Planning a cluster randomized controlled trial: methodological issues.
    Christie J; O'Halloran P; Stevenson M
    Nurs Res; 2009; 58(2):128-34. PubMed ID: 19289934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial design issues: at least 10 things you should look for in clinical trials.
    Glasser SP; Howard G
    J Clin Pharmacol; 2006 Oct; 46(10):1106-15. PubMed ID: 16988199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Who controls the placebo? Introducing a Placebo Quality Checklist for pharmacological trials.
    Brinkhaus B; Pach D; Lüdtke R; Willich SN
    Contemp Clin Trials; 2008 Mar; 29(2):149-56. PubMed ID: 17669693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Placebo-free designs for evaluating new mental health treatments: the use of adaptive treatment strategies.
    Dawson R; Lavori PW
    Stat Med; 2004 Nov; 23(21):3249-62. PubMed ID: 15490427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can clinical trials requiring frequent participant contact be conducted over the Internet? Results from an online randomized controlled trial evaluating a topical ointment for herpes labialis.
    Formica M; Kabbara K; Clark R; McAlindon T
    J Med Internet Res; 2004 Feb; 6(1):e6. PubMed ID: 15111272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placebo controls: scientific and ethical issues.
    Kowalski CJ
    Am J Bioeth; 2002; 2(2):33-4. PubMed ID: 12189073
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.